title: PharmGKB summary: very important pharmacogene information for MT-RNR1.
authors.affiliation: Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
authors.forename: Julia M
authors.initials: JM
authors.lastname: Barbarino
authors.forename: Tracy L
authors.initials: TL
authors.lastname: McGregor
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004272:DNA, Mitochondrial / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D034381:Hearing Loss / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D006801:Humans; D009154:Mutation; D010597:Pharmacogenetics; D012335:RNA, Ribosomal / Q000235:genetics*; D012264:Ribonucleotide Reductases / Q000235:genetics*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D004272:DNA, Mitochondrial; D012335:RNA, Ribosomal; C075526:RNA, ribosomal, 12S; D012264:Ribonucleotide Reductases